Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...
Hosted on MSN

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript May 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.50273 EPS, expectations ...
The Globe and Mail

Recursion Pharmaceuticals Announces Planned Board Leadership Transition

Recursion Pharmaceuticals ( (RXRX)) just unveiled an announcement. On April 28, 2026, Recursion Pharmaceuticals announced that founder and Chair of the Board Christopher Gibson, Ph.D., informed the ...
GEN

Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...